GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.
Publication/Presentation Date
5-14-2019
Abstract
We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival (CRFS) among pediatric patients with acute leukemia (n = 1613) who underwent transplantation with 1 antigen-mismatched (7/8) bone marrow (BM; n = 172) or umbilical cord blood (UCB; n = 1441). Multivariate analysis was performed using Cox proportional hazards models. To account for multiple testing,
Volume
3
Issue
9
First Page
1441
Last Page
1449
ISSN
2473-9537
Published In/Presented At
Mehta, R. S., Holtan, S. G., Wang, T., Hemmer, M. T., Spellman, S. R., Arora, M., Couriel, D. R., Alousi, A. M., Pidala, J., Abdel-Azim, H., Ahmed, I., Aljurf, M., Askar, M., Auletta, J. J., Bhatt, V., Bredeson, C., Chhabra, S., Gadalla, S., Gajewski, J., Gale, R. P., … Weisdorf, D. J. (2019). GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood advances, 3(9), 1441–1449. https://doi.org/10.1182/bloodadvances.2018030171
Disciplines
Medicine and Health Sciences
PubMedID
31053571
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article